期刊文献+

肝脏病人血浆凝血酶原的研究 被引量:5

To study Protllrombin of Plasma in Patients with Liver Disease
下载PDF
导出
摘要 目的:研究肝脏病人血浆凝血酶原的变化,并探讨其临床意义。方法:急性黄疸型乙型肝炎20例,肝硬化10例,原发性肝癌15例,对照组30例,用Ecarin-发色底物法检测其血浆中全凝血酶原量与吸附后凝血酶原量,PT用一期法测定。结果:所有患者PT延长,肝炎与肝硬化病人全凝血酶原量降低,肝癌病人增高;吸附后凝血酶原在肝癌病人增高显著,阳性为93.33%。结论:肝炎与肝硬化病人PT延长与全凝血酶原下降,可评估疾病严重程度并作为治疗监测。异常凝血酶原增高可用作原发性肝癌的筛选诊断。 Objective: To study the change of prothrombin in plasma on patients with liver disease and research its clinic significance. Methods: Acute jaundice B type hepatitis 20 cases, hepatic cirrhosis 10 cases, primary hep-atoma 15 cases, and control group 30 cases.The PT with one step method ,total prothrombin and after sbsorb prothrombin were deteminted with Ecarin-Chromogenic peptide substrate method. Results: All patients PT higher than controls. Total prothrombin are decreased in patients with hepatitis and cirrhosis, but increased in patients with primary hepatoma. After abosorb prothrombin(Abnormal prothrombin) are significant higher in primary depatoma than in control. Conclusion: PT delay and total prothrombin decreased in patients with hepatitis and cirrhosis and clear up serious degree of disease and monitor for treatment. Abnormal protherombin obvious increased can act as screeing diagnosis for primary hepatoma.
出处 《血栓与止血学》 2003年第3期106-107,共2页 Chinese Journal of Thrombosis and Hemostasis
关键词 肝脏病 血浆凝血酶原 肝炎 肝硬化 肝癌 Hepatits Cirrhosis Hepatoma Prothrombin
  • 相关文献

参考文献3

二级参考文献9

  • 1[1]Butenas S, van Veer C, Kenneth G. Mann " Normal" Thrombin Generation Blood, 1999,94:2169-2178.
  • 2[2]Bertina RM, vanTilburg NH, de Fouw, NJ, etal. Thrombin, alink between coagulation activation and fibrinolysis. Ann NY Acad Sci,1992,667: 239-248.
  • 3[3]Galvani M, Ferrini D, Ottani F, et al. Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. Int J Cardiol, 1999,68(Suppl 1 ) :55-61.
  • 4[4]Giannitsis E, Bardorff MM, Schweikart S, etal. Relationship of cardiac troponin T and procoagulant activity in unstable angina. Thromb Haemost, 2000,83: 224-228.
  • 5[6]Komalik F, Blomback B. Prothrombin activation induced by Ecarin-a prothrombin converting enzyme from Echis carinatus venom. Thromb Res, 1975,6: 57 -63.
  • 6[7]Nowak G, Bucha E. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res, 1995,80: 317-325.
  • 7[8]Potzsch B, Hund S, Madlener K, et al. Monitoring of recombinat rirudin: assessment of a plasma-based ecarin clotting time assay.Thromb Res, 1997,86: 373-383.
  • 8[9]Kornalik F. Prothrombin converting-and fibrinolytic effects of ecarin.Czech Med, 1985,8: 51-54.
  • 9[10]Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost, 1996,22:197-202.

共引文献2

同被引文献23

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部